{"groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"FG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"FG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"FG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"FG003","title":"Part 2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Elected to receive vobramitamab duocarmazine after protocol amendment 2."}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"91"},{"groupId":"FG001","numSubjects":"90"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"4"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"91"},{"groupId":"FG001","numSubjects":"90"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"4"}],"type":"Intent-to-treat Population"},{"achievements":[{"groupId":"FG000","numSubjects":"90"},{"groupId":"FG001","numSubjects":"86"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"}],"type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"59"},{"groupId":"FG001","numSubjects":"49"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"}],"type":"Tumor Response Evaluable Population"},{"achievements":[{"groupId":"FG000","numSubjects":"83"},{"groupId":"FG001","numSubjects":"71"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Prostate-specific Antigen (PSA) Response Evaluable Population"},{"achievements":[{"groupId":"FG000","numSubjects":"90"},{"groupId":"FG001","numSubjects":"86"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"4"}],"type":"Anti-drug Antibody (ADA) Evaluable Population"},{"achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"56"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"34"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}